Analytical development and testing for vaccine characterization can be a significant burden, and off-the-shelf validated immunoassays that save time can provide significant benefits. VaxArray® Platform is a new technology for multiplexed characterization
of vaccine antigens and antibody response and can complement or replace existing labor-intensive techniques such as ELISA, SRID, and cell culture-based infectivity measurements. This presentation will focus on case studies highlighting the
performance and utility of the VaxArray technology in different vaccine development, bioprocess, and clinical trial applications for a variety of vaccine types.
Save time and get more consistent results for your vaccine development or bioprocess optimization steps by learning new techniques which can replace or complement current laborious and lengthy tests such as ELISA, SRID, or TCID50. Run your assay
in hours instead of days, with better consistency across departments and sites using VaxArray kits.
Erica Dawson, PhD.
Chief Technical Officer
Dr. Dawson earned her Ph.D. in Analytical Chemistry from The University of North Carolina at Chapel Hill, holds a B.S. from Hartwick College in Oneonta, NY, and completed her postdoctoral training at the University of Colorado at Boulder with
research involving diagnostic DNA microarrays for influenza. Erica leads InDevR’s R&D and Engineering teams, has published a wide number of high impact scientific publications, and is a named inventor on numerous issued or pending
US and worldwide patents. She has been integral in leading the research and development and transfer to manufacturing of InDevR products since 2006.
Cost: No Cost!